Cargando…

Classification of Lung Adenocarcinoma Based on Immune Checkpoint and Screening of Related Genes

AIMS: Lung adenocarcinoma (LUAD) cells could escape from the monitoring of immune cells and metastasize rapidly through immune escape. Therefore, we aimed to develop a method to predict the prognosis of LUAD patients based on immune checkpoints and their associated genes, thus providing guidance for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Ting, Yang, Ping, Tang, Sanyuan, Zhu, Zhongshan, Li, Xiaobing, Yang, Zhou, Wu, Ruoxia, Tian, Xuefei, Li, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8337117/ https://www.ncbi.nlm.nih.gov/pubmed/34367284 http://dx.doi.org/10.1155/2021/5512325

Ejemplares similares

Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma
por: Wang, Qi, et al.
Publicado: (2023)

The Predictive Role of Immune Related Subgroup Classification in Immune Checkpoint Blockade Therapy for Lung Adenocarcinoma
por: Yu, Xiaozhou, et al.
Publicado: (2021)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
por: Sun, Hao, et al.
Publicado: (2020)

Immune Landscape and Classification in Lung Adenocarcinoma Based on a Novel Cell Cycle Checkpoints Related Signature for Predicting Prognosis and Therapeutic Response
por: Yang, Jian, et al.
Publicado: (2022)

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma
por: Yi, Ming, et al.
Publicado: (2021)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
por: Niu, Yuchun, et al.
Publicado: (2020)

Identification of an Immune Classification and Prognostic Genes for Lung Adenocarcinoma Based on Immune Cell Signatures
por: Deng, Lili, et al.
Publicado: (2022)

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Wen, Yang, et al.
Publicado: (2021)

Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy
por: Wang, Qinghua, et al.
Publicado: (2020)

EFNA3 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with lung adenocarcinoma
por: Deng, Mingming, et al.
Publicado: (2021)

Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma
por: Zhang, Youwei, et al.
Publicado: (2020)

Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma
por: Peng, Jie, et al.
Publicado: (2020)

Spatial distribution of immune checkpoint proteins in histological subtypes of lung adenocarcinoma
por: Müller, Sarah, et al.
Publicado: (2021)

Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases
por: Qiao, Meng, et al.
Publicado: (2021)

A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma
por: Guo, Dina, et al.
Publicado: (2020)

Receptor–ligand pair typing and prognostic risk model of response or resistance to immune checkpoint inhibitors in lung adenocarcinoma
por: Mao, Shengqiang, et al.
Publicado: (2023)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

A signature-based classification of lung adenocarcinoma that stratifies tumor immunity
por: Zhang, Xun, et al.
Publicado: (2023)

CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma
por: Zhang, Wengang, et al.
Publicado: (2022)

GDPLichi: a DNA Damage Repair-Related Gene Classifier for Predicting Lung Adenocarcinoma Immune Checkpoint Inhibitors Response
por: Leng, Yang, et al.
Publicado: (2021)

Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas
por: Tsukita, Yoko, et al.
Publicado: (2019)

Immune checkpoint inhibitors modulate the cytotoxic effect of chemotherapy in lung adenocarcinoma cells
por: Saar, Marika, et al.
Publicado: (2023)

Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma
por: Zhang, Hongpan, et al.
Publicado: (2022)

Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors
por: Liu, Sangtian, et al.
Publicado: (2020)

Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma
por: Kwok, Hoi-Hin, et al.
Publicado: (2023)

Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes
por: Hua, Linbin, et al.
Publicado: (2023)

Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
por: Liu, Wei, et al.
Publicado: (2020)

ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma
por: Zhang, Wengang, et al.
Publicado: (2022)

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020)

The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index
por: Zhang, Ting, et al.
Publicado: (2021)

Zc3h12d, a Novel of Hypomethylated and Immune-Related for Prognostic Marker of Lung Adenocarcinoma
por: Yang, Bo, et al.
Publicado: (2021)

CEACAM6 promotes cisplatin resistance in lung adenocarcinoma and is regulated by microRNA‐146a and microRNA‐26a
por: Du, He, et al.
Publicado: (2020)

Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
por: Li, Hong-Bo, et al.
Publicado: (2021)

Dual immunological and proliferative regulation of immune checkpoint FGL1 in lung adenocarcinoma: The pivotal role of the YY1–FGL1–MYH9 axis
por: Tang, Xi-Yang, et al.
Publicado: (2022)

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
por: Lin, Xinqing, et al.
Publicado: (2020)

The screening of immune-related biomarkers for prognosis of lung adenocarcinoma
por: Liu, Zhonghui, et al.
Publicado: (2021)

The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Haowei, et al.
Publicado: (2021)

Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma
por: Park, Sehhoon, et al.
Publicado: (2022)

Unraveling the Expression Patterns of Immune Checkpoints Identifies New Subtypes and Emerging Therapeutic Indicators in Lung Adenocarcinoma
por: Zhang, Jinguo, et al.
Publicado: (2022)

Typical tumor immune microenvironment status determine prognosis in lung adenocarcinoma
por: Ren, Caixia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qhg0tnglc1t3r02emfvht4udjo